A Phase 3 interventional study of Guselkumab and Placebo in Psoriasis, sponsored by Janssen Research & Development, LLC. Completed at 14 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-04.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies testing guselkumab in Psoriasis — 8 open to participants now, 9 under way, 1 of them phase 3. guselkumab · Psoriasis.
Among the 29 studies testing guselkumab in Psoriasis, this one is the 19th largest by enrollment, is one of 2 that started in 2017, is one of 12 in phase 3, and was the 9th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →8 of the 29 studies testing guselkumab in Psoriasis are open now, in 5 countries. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in United States
Ages 18+ · Women only
University Hospital, Ghent · Sites in Belgium
Ages 18+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18+
Fondazione Policlinico Universitario Campus Bio-Medico · Sites in Italy
Ages 18–80
University of California, San Francisco · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
guselkumab: first FDA approval 2017 (TREMFYA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 2 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 78 is close to the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 120 across the 29 interventional studies. Of the 20 that completed or were terminated, 12 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 29 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
76 studies in Psoriasis by Johnson & Johnson: 3 open now, 12 under way, 7 of them phase 3. Of 64 finished, 33 (52%) have results posted.
Among the 76 studies in Psoriasis by Johnson & Johnson, this one is the 42nd largest by enrollment of the 58 interventional ones that give a count, is one of 3 that started in 2017, is one of 36 in phase 3, and was the 49th registered.
Johnson & Johnson’s Psoriasis studies by the year they started, since 2002.
3 of the studies testing guselkumab in Psoriasis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05004727NYU Langone HealthMulti-Center PAMPA Study | 2026-12-31 |
| NCT07532486Second Affiliated Hospital, School of Medicine, Zhejiang UniversityA Study to Evaluate Comparative Efficacy and Safety of Guselkumab in High-dose and Extended-interval Versus Standard-dose in Chinese Participants of Moderate-to-severe Plaque Psoriasis | 2027-07-10 |
| NCT07654751Janssen Research & Development, LLCA Remotely Conducted Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically | 2027-08-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 29 studies testing guselkumab in Psoriasis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Johnson & Johnson’s 76 in Psoriasis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate the efficacy, safety, pharmacokinetics, immunogenicity, usability, and acceptability of guselkumab delivered using SelfDose device in participants with moderate to severe plaque-type psoriasis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive 100 milligram (mg) guselkumab administered as a 100 milligram per milliliter (mg/mL) solution in a single-use prefilled syringe (PFS) assembled in a SelfDose device at Weeks 0, 4, 12, 20, and 28; liquid placebo for guselkumab 100 mg at Week 16 to maintain the study blind.
Drug: Guselkumab · Drug: Placebo
Partcipants will receive placebo at Weeks 0, 4, and 12 followed by guselkumab 100 mg at Weeks 16, 20, and 28.
Drug: Guselkumab · Drug: Placebo
Participants will receive 100 mg of Guselkumab as 100 mg/mL solution via SelfDose device.
Also known as: CNTO 1959
Participants will receive matching placebo supplied in a PFS assembled in a SelfDose device.
Percentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of Cleared (0) or Minimal (1) at Week 16
The IGA documents the investigator's assessment of the participants psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4). Participants who achieved an IGA score of cleared (0) or minimal (1) were considered IGA cleared or minimal responders. Non-responder imputation (counted as non-responders) was applied for participants who met treatment failure rules, as well as for remaining missing data after treatment failure. Participants who discontinued study drug due to lack of efficacy, an adverse event (AE) of worsening of psoriasis, or who started a protocol-prohibited medication/therapy during study that could improve psoriasis were considered as treatment failures for the study.
Time frame: Week 16
Percentage of Participants Who Achieved a Psoriasis Area and Severity Index (PASI) 90 Response at Week 16
The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90 percent (%) to 100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that can range from 0 (no psoriasis) to 72. A higher score indicates more severe disease. A PASI 90 response represents participants who achieved at least a 90 percent improvement from baseline in the PASI score. Non-responder imputation (counted as non-responders) was applied for participants who met treatment failure rules, as well as for remaining missing data after treatment failure.
Time frame: Week 16
Percentage of Participants Who Achieve an IGA Score of Cleared (0) at Week 16
The IGA documents the investigator's assessment of the participants psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4). Participants who achieved an IGA score of cleared (0) were considered IGA cleared responders. Non-responder imputation (counted as non-responders) was applied for participants who met treatment failure rules, as well as for remaining missing data after treatment failure.
Time frame: Week 16
Percentage of Participants Who Achieve a PASI 100 Response at Week 16
The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90% to 100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that can range from 0 (no psoriasis) to 72. A higher score indicates more severe disease. Participants with 100% improvement in PASI from baseline (PASI score=0) were considered PASI 100 responders. Non-responder imputation (counted as non-responders) was applied for participants who met treatment failure rules, as well as for remaining missing data after treatment failure.
Time frame: Week 16
Percentage of Participants Who Achieved an IGA Score of Mild or Better (Less Than or Equal to [<=] 2) at Week 16
The IGA documents the investigator's assessment of the participants psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4). Participants who achieved an IGA score of cleared (0), minimal (1), or mild (2) were considered IGA mild or better responders. Non-responder imputation (counted as non-responders) was applied for participants who met treatment failure rules, as well as for remaining missing data after treatment failure.
Time frame: Week 16
Percentage of Participants Who Achieve a PASI 50 Response and a PASI 75 Response at Week 16
The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90% to 100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that can range from 0 (no psoriasis) to 72. A higher score indicates more severe disease. Participants with \>=50% and \>= 75% improvement in PASI from baseline were considered PASI 50 and PASI 75 responders respectively. Non-responder imputation (counted as non-responders) was applied for participants who met treatment failure rules, as well as for remaining missing data after treatment failure.
Time frame: Week 16
Percent Improvement From Baseline in PASI Score at Week 16
The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90% to 100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that can range from 0 (no psoriasis) to 72. A higher score indicates more severe disease. Participants were analyzed according to the assigned treatment to which they were randomized, regardless of the treatment they actually received.
Time frame: Baseline and Week 16
Percent Improvement From Baseline in PASI Score Through Week 40
The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90% to 100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that can range from 0 (no psoriasis) to 72. A higher score indicates more severe disease. Participants were analyzed according to the assigned treatment to which they were randomized, regardless of the treatment they actually received. From week 20, participants in placebo group, only included participants who crossed over to receive guselkumab at week 16.
Time frame: Baseline, Week 4, 8, 12, 20, 24, 28, 32, and Week 40 (4 weeks beyond the recommended every 8 weeks [q8w] dosing interval)
Percentage of Participants Who Achieved an IGA Score of Cleared (0), Cleared (0) or Minimal (1) and Mild or Better (<=2) Through Week 40
The IGA documents the investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4). Participants who achieved an IGA score of cleared (0) or minimal (1) were considered IGA cleared or minimal responders while those achieved an IGA score of cleared (0), minimal (1), or mild (2) were considered IGA mild or better responders. Participants were analyzed according to the assigned treatment to which they were randomized, regardless of the treatment they actually received. From week 20, participants in placebo group, only included participants who crossed over to receive guselkumab at week 16.
Time frame: Week 4, 8, 12, 20, 24, 28, 32, and Week 40 (4 weeks beyond the recommended q8w dosing interval)
Percentage of Participants Who Achieved PASI 100 Responses, PASI 90 Responses, PASI 75 Responses, and PASI 50 Responses
PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In PASI system, body is divided into 4 regions: head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90% to 100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. PASI produces a numeric score that can range from 0 (no psoriasis) to 72.Participants with \>=50%, \>= 75%, \>=90% and \>= 100% improvement in PASI from baseline were considered PASI 50, 75, 90 and PASI 100 responders, respectively. Participants were analyzed according to the assigned treatment to which they were randomized, regardless of the treatment they actually received. From week 20, participants in placebo group, only included participants who crossed over to receive guselkumab at week 16.
Time frame: Week 4, 8, 12, 16, 20, 24, 28, 32, and Week 40 (4 weeks beyond the recommended q8w dosing interval)
| Milestone | Placebo | Guselkumab | Placebo to Guselkumab |
|---|---|---|---|
| Started | 16 | 62 | 0 |
| Completed | 13 | 61 | 0 |
| Not completed | 3 | 1 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 |
| Withdrew: Lack of efficacy | 2 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 |
| Milestone | Placebo | Guselkumab | Placebo to Guselkumab |
|---|---|---|---|
| Started | 0 | 61 | 13 |
| Completed | 0 | 53 | 13 |
| Not completed | 0 | 8 | 0 |
| Withdrew: Other | 0 | 6 | 0 |
| Withdrew: Withdrawal by subject | 0 | 2 | 0 |
The IGA documents the investigator's assessment of the participants psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4). Participants who achieved an IGA score of cleared (0) or minimal (1) were considered IGA cleared or minimal responders. Non-responder imputation (counted as non-responders) was applied for participants who met treatment failure rules, as well as for remaining missing data after treatment failure. Participants who discontinued study drug due to lack of efficacy, an adverse event (AE) of worsening of psoriasis, or who started a protocol-prohibited medication/therapy during study that could improve psoriasis were considered as treatment failures for the study.
| Percentage of participants | Placebo | Guselkumab |
|---|---|---|
| Percentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of Cleared (0) or Minimal (1) at Week 16 | 0 | 80.6 |
The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90 percent (%) to 100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that can range from 0 (no psoriasis) to 72. A higher score indicates more severe disease. A PASI 90 response represents participants who achieved at least a 90 percent improvement from baseline in the PASI score. Non-responder imputation (counted as non-responders) was applied for participants who met treatment failure rules, as well as for remaining missing data after treatment failure.
| Percentage of participants | Placebo | Guselkumab |
|---|---|---|
| Percentage of Participants Who Achieved a Psoriasis Area and Severity Index (PASI) 90 Response at Week 16 | 0 | 75.8 |
The IGA documents the investigator's assessment of the participants psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4). Participants who achieved an IGA score of cleared (0) were considered IGA cleared responders. Non-responder imputation (counted as non-responders) was applied for participants who met treatment failure rules, as well as for remaining missing data after treatment failure.
| Percentage of participants | Placebo | Guselkumab |
|---|---|---|
| Percentage of Participants Who Achieve an IGA Score of Cleared (0) at Week 16 | 0 | 56.5 |
The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90% to 100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that can range from 0 (no psoriasis) to 72. A higher score indicates more severe disease. Participants with 100% improvement in PASI from baseline (PASI score=0) were considered PASI 100 responders. Non-responder imputation (counted as non-responders) was applied for participants who met treatment failure rules, as well as for remaining missing data after treatment failure.
| Percentage of participants | Placebo | Guselkumab |
|---|---|---|
| Percentage of Participants Who Achieve a PASI 100 Response at Week 16 | 0 | 50.0 |
The IGA documents the investigator's assessment of the participants psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4). Participants who achieved an IGA score of cleared (0), minimal (1), or mild (2) were considered IGA mild or better responders. Non-responder imputation (counted as non-responders) was applied for participants who met treatment failure rules, as well as for remaining missing data after treatment failure.
| Percentage of participants | Placebo | Guselkumab |
|---|---|---|
| Percentage of Participants Who Achieved an IGA Score of Mild or Better (Less Than or Equal to [<=] 2) at Week 16 | 0 | 93.5 |
The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90% to 100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that can range from 0 (no psoriasis) to 72. A higher score indicates more severe disease. Participants with \>=50% and \>= 75% improvement in PASI from baseline were considered PASI 50 and PASI 75 responders respectively. Non-responder imputation (counted as non-responders) was applied for participants who met treatment failure rules, as well as for remaining missing data after treatment failure.
| Percentage of participants | Placebo | Guselkumab |
|---|---|---|
| PASI 50 responders | 0 | 93.5 |
| PASI 75 responders | 0 | 88.7 |
The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90% to 100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that can range from 0 (no psoriasis) to 72. A higher score indicates more severe disease. Participants were analyzed according to the assigned treatment to which they were randomized, regardless of the treatment they actually received.
| Percent improvement | Placebo | Guselkumab |
|---|---|---|
| Percent Improvement From Baseline in PASI Score at Week 16 | 8.72 ± 18.229 | 91.53 ± 16.756 |
The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90% to 100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that can range from 0 (no psoriasis) to 72. A higher score indicates more severe disease. Participants were analyzed according to the assigned treatment to which they were randomized, regardless of the treatment they actually received. From week 20, participants in placebo group, only included participants who crossed over to receive guselkumab at week 16.
| Percent improvement | Placebo | Guselkumab |
|---|---|---|
| Week 4 | 5.58 ± 13.970 | 40.99 ± 26.377 |
| Week 8 | 10.45 ± 21.540 | 71.76 ± 26.984 |
| Week 12 | 13.76 ± 24.143 | 84.97 ± 20.520 |
| Week 20 | 62.65 ± 20.760 | 94.77 ± 13.179 |
| Week 24 | 88.74 ± 12.092 | 95.89 ± 10.164 |
| Week 28 | 95.68 ± 6.162 | 96.30 ± 7.504 |
| Week 32 | 96.16 ± 5.602 | 96.64 ± 7.143 |
| Week 40 | 97.70 ± 3.443 | 92.47 ± 13.289 |
The IGA documents the investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4). Participants who achieved an IGA score of cleared (0) or minimal (1) were considered IGA cleared or minimal responders while those achieved an IGA score of cleared (0), minimal (1), or mild (2) were considered IGA mild or better responders. Participants were analyzed according to the assigned treatment to which they were randomized, regardless of the treatment they actually received. From week 20, participants in placebo group, only included participants who crossed over to receive guselkumab at week 16.
| Percentage of participants | Placebo | Guselkumab |
|---|---|---|
| Week 4: IGA of cleared (0) | 0 | 4.8 |
| Week 4: IGA of cleared (0) or minimal (1) | 0 | 19.4 |
| Week 4: IGA of mild or better (<=2) | 0 | 54.8 |
| Week 8: IGA of cleared (0) | 0 | 19.4 |
| Week 8: IGA of cleared (0) or minimal (1) | 0 | 56.5 |
| Week 8: IGA of mild or better (<=2) | 12.5 | 85.5 |
| Week 12: IGA of cleared (0) | 0 | 35.5 |
| Week 12: IGA of cleared (0) or minimal (1) | 0 | 67.7 |
| Week 12: IGA of mild or better (<=2) | 0 | 91.9 |
| Week 20: IGA of cleared (0) | 0 | 67.7 |
| Week 20: IGA of cleared (0) or minimal (1) | 46.2 | 85.5 |
| Week 20: IGA of mild or better (<=2) | 92.3 | 93.5 |
| Week 24: IGA of cleared (0) | 38.5 | 71.0 |
| Week 24: IGA of cleared (0) or minimal (1) | 100.0 | 87.1 |
| Week 24: IGA of mild or better (<=2) | 100.0 | 88.7 |
| Week 28: IGA of cleared (0) | 61.5 | 64.5 |
| Week 28: IGA of cleared (0) or minimal (1) | 100.0 | 87.1 |
| Week 28: IGA of mild or better (<=2) | 100.0 | 95.2 |
| Week 32: IGA of cleared (0) | 69.2 | 66.1 |
| Week 32: IGA of cleared (0) or minimal (1) | 92.3 | 82.3 |
| Week 32: IGA of mild or better (<=2) | 100.0 | 90.3 |
| Week 40: IGA of cleared (0) | 61.5 | 53.2 |
| Week 40: IGA of cleared (0) or minimal (1) | 92.3 | 71.0 |
| Week 40:IGA of mild or better (<=2) | 100.0 | 79.0 |
PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In PASI system, body is divided into 4 regions: head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90% to 100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. PASI produces a numeric score that can range from 0 (no psoriasis) to 72.Participants with \>=50%, \>= 75%, \>=90% and \>= 100% improvement in PASI from baseline were considered PASI 50, 75, 90 and PASI 100 responders, respectively. Participants were analyzed according to the assigned treatment to which they were randomized, regardless of the treatment they actually received. From week 20, participants in placebo group, only included participants who crossed over to receive guselkumab at week 16.
| Percentage of participants | Placebo | Guselkumab |
|---|---|---|
| Week 4: 100% improvement | 0 | 3.2 |
| Week 4: >= 90% improvement | 0 | 4.8 |
| Week 4: >= 75% improvement | 0 | 12.9 |
| Week 4: >= 50% improvement | 0 | 33.9 |
| Week 8: 100% improvement | 0 | 16.1 |
| Week 8: >= 90% improvement | 0 | 33.9 |
| Week 8: >= 75% improvement | 0 | 56.5 |
| Week 8: >= 50% improvement | 6.3 | 80.6 |
| Week 12: 100% improvement | 0 | 30.6 |
| Week 12: >= 90% improvement | 0 | 54.8 |
| Week 12: >= 75% improvement | 0 | 77.4 |
| Week 12: >= 50% improvement | 12.5 | 90.3 |
| Week 16: 100% improvement | 0 | 50.0 |
| Week 16: >=90% improvement | 0 | 75.8 |
| Week 16: >=75% improvement | 0 | 88.7 |
| Week 16: >=50% improvement | 0 | 93.5 |
| Week 20: 100% improvement | 0 | 66.1 |
| Week 20: >=90% improvement | 7.7 | 85.5 |
| Week 20: >=75% improvement | 30.8 | 91.9 |
| Week 20: >=50% improvement | 69.2 | 95.2 |
| Week 24: 100% improvement | 30.8 | 71.0 |
| Week 24: >=90% improvement | 61.5 | 82.3 |
| Week 24: >=75% improvement | 84.6 | 88.7 |
| Week 24: >=50% improvement | 100.0 | 95.2 |
| Week 28: 100% improvement | 53.8 | 64.5 |
| Week 28: >=90% improvement | 84.6 | 85.5 |
| Week 28: >=75% improvement | 100.0 | 95.2 |
| Week 28: >50% improvement | 100.0 | 96.8 |
| Week 32: 100% improvement | 61.5 | 64.5 |
| Week 32: >=90% improvement | 84.6 | 85.5 |
| Week 32: >=75% improvement | 100.0 | 90.3 |
| Week 32: >=50% improvement | 100.0 | 93.5 |
| Week 40: 100% improvement | 53.8 | 53.2 |
| Week 40: >=90% improvement | 100.0 | 66.1 |
| Week 40: >=75% improvement | 100.0 | 79.0 |
| Week 40: >=50% improvement | 100.0 | 79.0 |
Collected over Up to Week 40. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo (Week 0-16) | 0/16 (0%) | 0/16 (0%) | 12/16 (75%) |
| Guselkumab (Week 0-16) | 0/62 (0%) | 2/62 (3.2%) | 38/62 (61.3%) |
| Placebo to Guselkumab (Week 16-40) | 0/13 (0%) | 2/13 (15.4%) | 8/13 (61.5%) |
| Guselkumab (Week 16-40) | 0/61 (0%) | 1/61 (1.6%) | 24/61 (39.3%) |
| Event | Placebo (Week 0-16) | Guselkumab (Week 0-16) | Placebo to Guselkumab (Week 16-40) | Guselkumab (Week 16-40) |
|---|---|---|---|---|
| Angina PectorisCardiac disorders | 0/16 | 0/62 | 1/13 | 0/61 |
| DiverticulitisInfections and infestations | 0/16 | 0/62 | 1/13 | 0/61 |
| Drug HypersensitivityImmune system disorders | 0/16 | 0/62 | 0/13 | 1/61 |
| Chest DiscomfortGeneral disorders | 0/16 | 1/62 | 0/13 | 0/61 |
| Chest PainGeneral disorders | 0/16 | 1/62 | 0/13 | 0/61 |
| Event | Placebo (Week 0-16) | Guselkumab (Week 0-16) | Placebo to Guselkumab (Week 16-40) | Guselkumab (Week 16-40) |
|---|---|---|---|---|
| Injection Site PainGeneral disorders | 7/16 | 25/62 | 3/13 | 11/61 |
| Injection Site ColdnessGeneral disorders | 3/16 | 14/62 | 2/13 | 7/61 |
| Injection Site PruritusGeneral disorders | 2/16 | 8/62 | 1/13 | 2/61 |
| Injection Site IndurationGeneral disorders | 2/16 | 7/62 | 1/13 | 2/61 |
| Injection Site ErythemaGeneral disorders | 1/16 | 7/62 | 0/13 | 4/61 |
| Injection Site SwellingGeneral disorders | 1/16 | 7/62 | 1/13 | 3/61 |
| Viral Upper Respiratory Tract InfectionInfections and infestations | 0/16 | 3/62 | 1/13 | 6/61 |
| Upper Respiratory Tract InfectionInfections and infestations | 0/16 | 5/62 | 0/13 | 1/61 |
| AnaemiaBlood and lymphatic system disorders | 0/16 | 0/62 | 1/13 | 1/61 |
| Left Ventricular HypertrophyCardiac disorders | 0/16 | 0/62 | 1/13 | 0/61 |
| Age, Continuous(years) | Placebo | Guselkumab | Total |
|---|---|---|---|
| Mean | 45.4 ± 15.7 | 46.2 ± 12.92 | 46 ± 13.43 |
| Age, Customized(Participants) | Placebo | Guselkumab | Total |
|---|---|---|---|
| >=18 to 65 years | 14 | 58 | 72 |
| >=65 years | 2 | 4 | 6 |
| Sex: Female, Male(Participants) | Placebo | Guselkumab | Total |
|---|---|---|---|
| Female | 4 | 21 | 25 |
| Male | 12 | 41 | 53 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Guselkumab | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 2 | 3 |
| Not Hispanic or Latino | 15 | 60 | 75 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | Guselkumab | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 2 | 3 | 5 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 1 | 2 |
| White | 13 | 57 | 70 |
| More than one race | 0 | 1 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Placebo | Guselkumab | Total |
|---|---|---|---|
| Asian | 2 | 3 | 5 |
| Black or African American | 1 | 1 | 2 |
| Hispanic or Latino | 0 | 2 | 2 |
| Other | 0 | 1 | 1 |
| White Non-Hispanic | 13 | 55 | 68 |
| Region of Enrollment(Participants) | Placebo | Guselkumab | Total |
|---|---|---|---|
| Canada | 5 | 19 | 24 |
| Poland | 5 | 20 | 25 |
| United States | 6 | 23 | 29 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Feb 2017 to primary completion in Feb 2018, 11 months.
Results were first posted in Sep 2018, 7 months after primary completion.
Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 11 months is below that.
Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Guselkumab
Janssen Research & Development, LLC →